Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial
| Autor: | Mosenzon, Ofri a, *, Wiviott, Stephen D b, Cahn, Avivit a, Rozenberg, Aliza a, Yanuv, Ilan a, Goodrich, Erica L b, Murphy, Sabina A b, Heerspink, Hiddo J L c, Zelniker, Thomas A b, Dwyer, Jamie P d, Bhatt, Deepak L b, Leiter, Lawrence A e, McGuire, Darren K f, Wilding, John P H g, Kato, Eri T h, Gause-Nilsson, Ingrid A M i, Fredriksson, Martin i, Johansson, Peter A i, Langkilde, Anna Maria i, Sabatine, Marc S b, Raz, Itamar a |
|---|---|
| Zdroj: | In The Lancet Diabetes & Endocrinology August 2019 7(8):606-617 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|